
    
      Data to be collected from the time of onset of symptoms related to TK2 deficiency includes
      medical conditions and/or adverse events (AEs); these should include relationship to TK2
      disease and/or pyrimidine nucleosides, as appropriate, as well as date of onset and severity,
      when available. When available, test reports may be obtained as well as available research
      biological samples (eg, blood or tissue samples that may be tested for biomarkers of disease
      and/or effects of medications to treat the mitochondrial disease).
    
  